Mark Stevenson has been promoted to executive vice president and chief operation officer of Thermo Fisher Scientific, effective August 1. In his new role, he will oversee operations of the company's Laboratory Products and Analytical Instruments businesses, in addition to the Life Sciences Solutions business. Since 2014, when Thermo Fisher acquired Life Technologies, Stevenson has been executive vice president and president of Life Sciences Solutions. Prior to that, he was president and chief operating officer of Life Technologies, and before that, he was president and COO of Applied Biosystems.
Hans Bishop has been elected to Agilent's board of directors. Bishop is cofounder, president, and CEO of Juno Therapeutics, a Seattle-based biopharmaceutical company. He has also held a range of executive positions in the pharmaceutical industry, including as COO at Dendreon; president of Specialty Medicine at Bayer Healthcare; and global commercial head for Chiron.
Quanterix has appointed Daniel Sikkema as vice president of acclerator services for the company's new Simoa Accelerator Lab, a dedicated environment for biomarker research, custom assay development, and clinical sample testing. Sikkema will work to expand the reach of Quanterix's Accelerator Lab services in neurology, oncology, immuno-oncology, infectious disease, inflammatory diseases, and other therapeutic areas. He has previously worked at Frontage Lab, Bristol-Myers Squibb, Wyeth, Merck, Sanofi Pasteur, and GlaxoSmithKline.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.